NEW YORK—Kalorama Information noted in a recent report that
the personalized medicine testing market surpassed $28 billion in 2011. Tests
for personalized medicine continue to gain popularity, especially in oncology,
where many new medicines come paired with diagnostic assays. The tests are most
popular in this area given the need to determine ideal methods of treatment
individually and improve survival rates for patients. Tissue tests, such as
immunohistochemical stains and in-situ
hybridization, that determine which therapy to pursue for cancer treatment are
what have been turning personalized medicine into a reality, the report notes.
These tests are expected to experience better-than-average IVD industry revenue
growth rates in the next five years. Kalorama listed Abbott Diagnostics, Dako
and Roche/Ventana Medical as the market leaders in pharmacodiagnostic
histology.